Home Plasma creatinine medians from patients partitioned by gender and age used as a tool for assessment of analytical stability at different concentrations
Article
Licensed
Unlicensed Requires Authentication

Plasma creatinine medians from patients partitioned by gender and age used as a tool for assessment of analytical stability at different concentrations

  • Steen Ingemann Hansen EMAIL logo , Per Hyltoft Petersen , Flemming Lund and Callum G. Fraser
Published/Copyright: August 5, 2019

Abstract

Background

Monthly medians of patient results are useful in assessment of analytical quality in medical laboratories. Separate medians by gender makes it possible to generate two independent estimates of contemporaneous errors. However, for plasma creatinine, reference intervals (RIs) are different by gender and also higher over 70 years of age.

Methods

Daily, weekly and monthly patient medians were calculated from the raw data of plasma creatinine concentrations for males between 18 and 70 years, males >70 years, females between 18 and 70 years and females >70 years.

Results

The medians of the four groups were all closely associated, with similar patterns. The mean of percentage bias from each group defined the best estimate of bias. The maximum half-range (%) of the bias evaluations provided an estimate of the uncertainty comparable to the analytical performance specifications: thus, bias estimates could be classified as optimum, desirable or minimum quality.

Conclusions

Medians by gender and age are useful in assessment of analytical stability for plasma creatinine concentration ranging from 60 to 90 μmol/L. The daily medians are valuable in rapid detection of large systematic errors, the weekly medians in detecting minor systematic errors and monthly medians in assessment of long-term analytical stability.

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: None declared.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: The funding organisation(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Lott JA, Smith DA, Mitchell LC, Moeschberger ML. Use of medians and “average of normals” of patients’ data for assessment of long-term analytical stability. Clin Chem 1996;42:888–92.10.1093/clinchem/42.6.888Search in Google Scholar

2. Jørgensen LM, Hansen SI, Petersen PH, Sölétormos G. Median of patient results as a tool for assessment of analytical stability. Clin Chim Acta 2015;446:186–91.10.1016/j.cca.2015.04.024Search in Google Scholar PubMed

3. Hansen SI, Petersen PH, Lund F, Fraser CG, Sölétormos G. Separate patient serum sodium medians from males and femalesprovide independent information on analytical bias. Clin Chem Lab Med 2017;55:1865–72.10.1515/cclm-2016-1010Search in Google Scholar PubMed

4. Hansen SI, Petersen PH, Lund F, Fraser CG, Sölétormos G. Gender-partitioned patient medians of serum albumin requested by general practitioners for the assessment of analytical stability. Clin Chem Lab Med 2017;56:843–50.10.1515/cclm-2017-0771Search in Google Scholar PubMed

5. Fraser CG, Petersen PH, Libeer J-C, Ricós C. Proposals for setting generally applicable quality goals solely based on biology. Ann Clin Biochem 1997;34:8–12.10.1177/000456329703400103Search in Google Scholar PubMed

6. Rustad P, Felding P, Franzon L, Kairisto V, Lahti A, Mårtensson A, et al. The Nordic reference interval project 2000: recommended reference intervals for 25 common biochemical properties. Scand J Clin Lab Invest 2004;64:271–84.10.1080/00365510410006324Search in Google Scholar PubMed

7. Carlsson L, Lind L, Larsson A. Reference values for 27 clinical chemistry tests in 70-year-old males and females. Gerontology 2010;56:259–65.10.1159/000251722Search in Google Scholar PubMed

8. Carobene A, Marino I, Coscum A, Serteser M, Unsal I, Guerra E, et al. The EuBIVAS project: within- and between-subject biological variation data for serum creatinine using enzymatic and alkaline picrate methods and implications for monitoring. Clin Chem 2017;63:1527–36.10.1373/clinchem.2017.275115Search in Google Scholar PubMed

9. Helmerson-Karlqvist J, Ridefelt P, Lind L, Larsson A. Normalvärden för 80-åriga män och kvinnor bosatta i Norden. Klinisk Biokemi i Norden 2018;30:26–30.Search in Google Scholar

10. Myers GL, Miller WG, Coresh J, Fleming J, Greenberg N, GreeneT, et al. Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. Clin Chem 2006;52:5–18.10.1373/clinchem.2005.0525144Search in Google Scholar PubMed

11. Jassam N, Weykamp C, Thomas A, Secchiero S, Sciacovelli L, Plebani M, et al. Post-standardization of routine creatinine assays: are they suitable for clinical applications. Ann Clin Biochem 2017;53:386–94.10.1177/0004563216664541Search in Google Scholar PubMed

Received: 2019-03-26
Accepted: 2019-07-12
Published Online: 2019-08-05
Published in Print: 2019-12-18

© 2020 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Frontmatter
  2. Editorial
  3. Reflex TSH strategy: the good, the bad and the ugly
  4. Review
  5. Shortcomings in the evaluation of biomarkers in ovarian cancer: a systematic review
  6. Mini Review
  7. Clinical application of presepsin as diagnostic biomarker of infection: overview and updates
  8. Opinion Paper
  9. Gut microbiotas and immune checkpoint inhibitor therapy response: a causal or coincidental relationship?
  10. EFLM Paper
  11. Systematic review and meta-analysis of within-subject and between-subject biological variation estimates of 20 haematological parameters
  12. General Clinical Chemistry and Laboratory Medicine
  13. Pre-, post- or no acidification of urine samples for calcium analysis: does it matter?
  14. Pre-analytical and analytical confounders of serum calprotectin as a biomarker in rheumatoid arthritis
  15. Dynamics of soluble syndecan-1 in maternal serum during and after pregnancies complicated by preeclampsia: a nested case control study
  16. Multi-site performance evaluation and Sigma metrics of 20 assays on the Atellica chemistry and immunoassay analyzers
  17. Plasma creatinine medians from patients partitioned by gender and age used as a tool for assessment of analytical stability at different concentrations
  18. Two-center comparison of 10 fully-automated commercial procalcitonin (PCT) immunoassays
  19. Method comparison of four clinically available assays for serum free light chain analysis
  20. Comparison of three different chemiluminescence assays and a rapid liquid chromatography tandem mass spectrometry method for measuring serum aldosterone
  21. Repeatability and reproducibility of lipoprotein particle profile measurements in plasma samples by ultracentrifugation
  22. Reference Values and Biological Variations
  23. A study on reference interval transference via linear regression
  24. Cancer Diagnostics
  25. Unstimulated high-sensitive thyroglobulin is a powerful prognostic predictor in patients with thyroid cancer
  26. Cardiovascular Diseases
  27. Analytical validation of a highly sensitive point-of-care system for cardiac troponin I determination
  28. Acknowledgment
  29. Letters to the Editor
  30. Are icteric and lipemic indices reliable to screen for hyperbilirubinemia and hypertriglyceridemia?
  31. Anti-streptavidin antibodies as a cause of false-positive results of streptavidin-based autoantibody assays
  32. Assessment of complement interference in anti-Müllerian hormone immunoassays
  33. Validating thyroid-stimulating hormone (TSH) reflexive testing cutpoints in a tertiary care institution
  34. Results of the second external quality assessment for human papillomavirus genotyping in Shanghai, China
  35. Development of suitable external quality control material for G6PD deficiency screening with the fluorescent spot test
  36. Non-linearity in commercially available lipase assays: still gaps to close
  37. JAK2, 46/1 haplotype and chronic myelogenous leukemia: diagnostic and therapeutic potential
  38. Congress Abstracts
  39. 11th National Scientifc Congress SPML
Downloaded on 17.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/cclm-2019-0334/html
Scroll to top button